| Index | — | P/E | 10.37 | EPS (ttm) | 1.72 | Insider Own | 4.58% | Shs Outstand | 72.39M | Perf Week | 9.45% |
| Market Cap | 1.29B | Forward P/E | 16.86 | EPS next Y | 1.06 | Insider Trans | -3.42% | Shs Float | 69.29M | Perf Month | -4.19% |
| Enterprise Value | 1.24B | PEG | 0.27 | EPS next Q | 0.02 | Short Float | 16.50% | Perf Quarter | 37.79% | ||
| Income | 124.00M | P/S | 33.09 | EPS this Y | — | Short Ratio | 6.69 | Perf Half Y | 19.58% | ||
| Sales | 39.00M | P/B | — | EPS next Y | 28.15% | ROA | 43.52% | Short Interest | 11.43M | Perf YTD | 3.78% |
| Book/sh | -0.70 | P/C | 9.78 | EPS next 5Y | 38.44% | ROE | — | 52W High | 21.24 -14.88% | Perf Year | 137.10% |
| Cash/sh | 1.82 | P/FCF | — | EPS past 3/5Y | — | ROIC | -31.14% | 52W Low | 6.24 189.74% | Perf 3Y | 1543.32% |
| Dividend Est. | — | EV/EBITDA | 9.36 | Sales past 3/5Y | — | Gross Margin | 95.77% | Volatility | 6.38% 4.80% | Perf 5Y | 182.12% |
| Dividend TTM | — | EV/Sales | 31.68 | EPS Y/Y TTM | — | Oper. Margin | -189.53% | ATR (14) | 0.93 | Perf 10Y | 109.27% |
| Dividend Ex-Date | — | Quick Ratio | 1.94 | Sales Y/Y TTM | — | Profit Margin | — | RSI (14) | 49.54 | Recom | 2.42 |
| Dividend Gr. 3/5Y | — | Current Ratio | 1.95 | EPS Q/Q | 134.88% | SMA20 | -0.28% | Beta | 2.99 | Target Price | 27.50 |
| Payout | 0.00% | Debt/Eq | — | Sales Q/Q | — | SMA50 | -3.58% | Rel Volume | 0.54 | Prev Close | 17.83 |
| Employees | 175 | LT Debt/Eq | — | Earnings | Nov 12 | SMA200 | 31.93% | Avg Volume | 1.67M | Price | 18.08 |
| IPO Date | Oct 08, 2009 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 155.91% — | Net Debt/EBITDA | -0.42 | Volume | 903,477 | Change | 1.40% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Sep-22-26 | Upgrade | Cantor Fitzgerald | Neutral → Overweight | $22 |
| Jun-26-26 | Reiterated | HC Wainwright & Co. | Buy | $40 → $33 |
| Jan-08-26 | Reiterated | HC Wainwright & Co. | Buy | $20 → $40 |
| Oct-15-25 | Reiterated | HC Wainwright & Co. | Buy | $9.00 → $20 |
| Jun-27-25 | Reiterated | H.C. Wainwright | Buy | $9.00 |
| Nov-10-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral | |
| Dec-08-22 | Downgrade | UBS | Buy → Neutral | $2.00 |
| Nov-08-22 | Downgrade | B of A Securities | Neutral → Underperform | |
| Jun-08-22 | Downgrade | B of A Securities | Buy → Neutral | |
| Oct-08-21 | Downgrade | JP Morgan | Neutral → Underweight |
Omeros Corporation is a biopharmaceutical firm with commercialized products, actively engaged in the discovery, development, and market introduction of both small-molecule and protein-based therapies, including treatments for rare diseases. The company's therapeutic endeavors primarily focus on inflammatory conditions, illnesses mediated by the complement system, cancers linked to immune system dysregulation, and disorders characterized by addiction or compulsion. Its robust clinical pipeline features several promising candidates. Narsoplimab (also known as OMS721 or MASP-2), a leading asset, has successfully concluded pivotal trials for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA). This drug is also currently undergoing Phase III clinical evaluation for immunoglobulin A nephropathy (IgAN) and atypical hemolytic uremic syndrome (aHUS), in addition to a Phase II trial investigating its potential for treating COVID-19. Further expanding its clinical portfolio, Omeros is developing PPAR? (OMS405) in Phase II for opioid and nicotine dependence. PDE7 (OMS527) is progressing through Phase I studies for addiction, compulsive disorders, and movement disorders. Additionally, MASP-3 (OMS906) is currently in Phase I trials for paroxysmal nocturnal hemoglobinuria (PNH) and other conditions involving the alternative complement pathway. Beyond its clinical efforts, the company maintains a dynamic preclinical program. This includes small-molecule inhibitors targeting MASP-2, which are being explored for applications in aHUS, IgAN, HSCT-TMA, and age-related macular degeneration. Also in development is a next-generation, longer-acting antibody that targets MASP-2, alongside MASP-3 small-molecule inhibitors designed to address PNH and other alternative pathway disorders. Omeros's preclinical research further encompasses GPR174 inhibitors, as well as Chimeric Antigen Receptor (CAR) T-Cell and Adoptive T-Cell Therapies for various oncological indications. The company is also investigating G protein-coupled receptor targets for a broad spectrum of diseases, including immunological, immuno-oncological, metabolic, central nervous system (CNS), cardiovascular, musculoskeletal, and other conditions. Established in 1994, Omeros Corporation is headquartered in Seattle, Washington.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 39 | 0 | 0 | 0 | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 2 | 0 | 0 | 0 | — | — | — | — | — | |
| Gross Profit | 37 | 0 | 0 | 0 | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 47 | 42 | 50 | 50 | — | — | — | — | — | |
| Research and Development | 62 | 81 | 120 | 115 | — | — | — | — | — | |
| Other Operating Expense | 0 | 0 | -1 | 0 | — | — | — | — | — | |
| Operating Income | -72 | -123 | -169 | -165 | — | — | — | — | — | |
| Interest Expense | 23 | 0 | 25 | 31 | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 214 | 120 | 11 | 20 | — | — | — | — | — | |
| Net Income Before Taxes | 119 | -3 | -183 | -175 | — | — | — | — | — | |
| Income Taxes | 2 | 2 | 0 | 0 | — | — | — | — | — | |
| Consolidated Net Income | 124 | -3 | -157 | -118 | — | — | — | — | — | |
| Net Income From Continuing Operations | 117 | -5 | -183 | -175 | — | — | — | — | — | |
| Net Income | 124 | -3 | -157 | -118 | — | — | — | — | — | |
| EPS (Recurring) | 1.91 | -0.05 | -2.70 | -1.88 | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | 1.91 | -0.05 | -2.70 | -1.88 | — | — | — | — | — | |
| EPS (Diluted) | 1.72 | -0.05 | -2.70 | -1.88 | — | — | — | — | — | |
| EBITDA | 132 | -2 | -157 | -143 | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | 10.51 | — | — | — | — | — | — | — | — | |
| Price To Sales Ratio | 33.38 | — | — | — | — | — | — | — | — | |
| Gross Margin | 94.87 | — | — | — | — | — | — | — | — | |
| Operating Margin | -184.62 | — | — | — | — | — | — | — | — | |
| Net Margin | 317.95 | — | — | — | — | — | — | — | — | |
| Shares Outstanding | 72 | 64 | 58 | 63 | — | — | — | — | — | |
| Market Capitalization | 1,302 | 1,100 | 573 | 206 | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Borges David J. | VP, Finance & CAO | Sep 23 '26 | Option Exercise | 15.58 | 10,000 | 155,800 | 10,000 | Sep 24 |
| Borges David J. | VP, Finance & CAO | Sep 23 '26 | Sale | 20.95 | 10,000 | 209,500 | 0 | Sep 24 |
| Borges David J. | VP, Finance & CAO | Sep 22 '26 | Option Exercise | 3.44 | 10,000 | 34,350 | 10,000 | Sep 24 |
| Cancelmo Peter B | VP, General Counsel | Aug 31 '26 | Option Exercise | 2.94 | 25,000 | 73,500 | 25,200 | Sep 01 |
| Cancelmo Peter B | VP, General Counsel | Aug 31 '26 | Sale | 18.54 | 25,000 | 463,540 | 200 | Sep 01 |
| Cancelmo Peter B | VP, General Counsel | Aug 28 '26 | Option Exercise | 2.94 | 25,000 | 73,500 | 75,000 | Sep 01 |
| Cancelmo Peter B | VP, General Counsel | Aug 28 '26 | Sale | 18.65 | 25,000 | 466,128 | 200 | Sep 01 |
| HANISH ARNOLD C | Director | Aug 27 '26 | Sale | 18.95 | 10,000 | 189,462 | 0 | Aug 28 |
| HANISH ARNOLD C | Director | Aug 27 '26 | Option Exercise | 14.95 | 10,000 | 149,475 | 10,000 | Aug 28 |
| HANISH ARNOLD C | Director | Aug 26 '26 | Option Exercise | 15.81 | 5,000 | 79,050 | 5,000 | Aug 28 |
| HANISH ARNOLD C | Director | Aug 26 '26 | Sale | 18.53 | 5,000 | 92,633 | 0 | Aug 28 |
| Borges David J. | VP, Finance & CAO | Aug 24 '26 | Option Exercise | 2.94 | 906 | 2,664 | 906 | Aug 25 |
| Borges David J. | VP, Finance & CAO | Aug 24 '26 | Sale | 19.10 | 906 | 17,305 | 0 | Aug 25 |
| Borges David J. | VP, Finance & CAO | Aug 21 '26 | Option Exercise | 3.52 | 10,000 | 35,247 | 10,000 | Aug 25 |
| Borges David J. | VP, Finance & CAO | Aug 21 '26 | Sale | 18.95 | 10,000 | 189,500 | 0 | Aug 25 |